Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03373877
Other study ID # PU-H71-01-002
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date May 24, 2018
Est. completion date March 10, 2020

Study information

Verified date November 2022
Source Samus Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter 2-part, Phase 1b study designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of PU-H71 in subjects taking concomitant ruxolitinib. The first part (Dose Escalation) will employ a standard 3+3 dose escalation design to determine Maximum Tolerated Dose (MTD). The second part of the study (Dose Confirmation) will confirm the recommended Phase 2 dose (RP2D) in an expanded population.


Description:

This is a multicenter 2-part, Phase 1b study designed to assess the safety, tolerability, PK and preliminary efficacy of PU-H71 (dihydrochloride salt) in subjects taking concomitant ruxolitinib. The first part (Dose Escalation) will employ a standard 3+3 dose escalation design to determine MTD. The second part of the study (Dose Confirmation) will confirm the RP2D in an expanded population. Up to 30 subjects who have active disease despite having received a minimum of 6 months of ruxolitinib therapy (including last 2 months at a daily dose of ≥5 mg twice daily and no more than one dose reduction 2-8 weeks prior to the baseline visit)stable dose will be enrolled to evaluate the safety, PK, and MTD of IV PU-H71 administered in combination ruxolitinib. Four ascending dose levels are planned. The planned dose levels of PU-H71 are 225 mg/m2, 300 mg/m2, 400 mg/m2, and 600 mg/m2. Additional dosing cohorts may be added at the discretion of the Safety Review Committee (SRC). Following a 28-day screening period, eligible subjects will receive PU-H71 once weekly intravenously for three consecutive weeks, followed by one week off on a 28-day cycle (D1, D8, D15, every 28 days). Ruxolitinib will be administered twice daily per the package insert at the stable dose the subject had been receiving prior to enrolling in the study. Subjects will have pk samples taken and ECGs performed at various time points throughout the study. Subjects will have safety evaluations including physical examinations, vital signs, laboratory assessments, and AE reporting. If deemed necessary, additional safety measurements will be performed at the discretion of the Investigator or the SRC. Subjects will be treated until disease progression, DLT, death, or study termination. At each dose level, a 3+3 dose escalation design will be employed. If none of the initial 3 subjects in the cohort experience a DLT within the first cycle, a new cohort of 3 subjects will be treated at the next higher dose level. If 1 of the 3 subjects in a cohort experiences a DLT, then 3 additional subjects will be treated at the same dose level as described under Dose Limiting Toxicities. Once the MTD has been determined in the dose escalation portion of the study, up to 15 patients may be enrolled for further evaluation of safety, PK, and preliminary clinical activity in a dose confirmation phase. A safety review committee (SRC) will assess the safety, tolerability, and available PK information collected for each dose level, decide whether to proceed to the next cohort, and determine the dose for the cohort.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date March 10, 2020
Est. primary completion date October 17, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subject has a confirmed diagnosis of myelofibrosis, including PMF, post-PV MF, and post-ET MF. 2. Subject has been receiving ruxolitinib therapy for intermediate or high-risk myelofibrosis for >6 months prior to enrollment with no more than 1 dose reduction of ruxolitinib in the 2-8 weeks prior to enrollment and a stable daily dose =5 mg twice daily (BID) >2 months prior to enrollment. 3. Subject has MF with evidence of persistent disease despite ruxolitinib monotherapy treatment, consisting of: 1. Persistent or worsening disease-related symptoms, including but not limited to fatigue, pruritus, night sweats, early satiety, and other symptoms as determined by a MPN-SAF TSS score of >20 points; AND 2. Documented splenomegaly of at least 5 cm below the costal margin as measured on inspiration by physical exam. 4. Subject has an Eastern Cooperative Oncology Group performance status of 0-2. 5. Acceptable pre-study organ function during screening defined as: 1. Absolute neutrophil count (ANC) = 1000/uL 2. Hemoglobin (hgb) = 8.0 g/dL (may be supported with transfusion) 3. Platelets (plt) = 75,000/uL 4. AST/SGOT and ALT/SGPT =2 x Upper Limit of Normal (ULN) 5. Direct serum bilirubin = 1.5 x ULN 6. Creatinine clearance >50 mL/min/1.73 m2 based on Cockcroft Gault equation. Exclusion Criteria: 1. Subject has known active liver disease, including viral hepatitis or cirrhosis. 2. Subject has known or suspected HIV or other active infections requiring acute or chronic treatment with systemic antibiotics. Conditions requiring topical antibiotics are acceptable. 3. Subject has a QTcF > 480 ms (corrected) in the screening or baseline ECG. 4. Subject has left ventricular ejection fraction (LVEF) = 50%, or below institution's lower limit of normal (whichever is lower) by echocardiogram (ECHO) or multigated acquisition (MUGA) scan. 5. Subject has a history (or family history) of long QT syndrome. 6. Subject has coronary artery disease with an ischemic event within 6 months prior to enrollment. 7. Subject has a permanent cardiac pacemaker. 8. Subject has history of a second primary malignancy within the past 2 year except for the following (if appropriately treated and considered cured): stage I endometrial, surgically treated cervical or prostate carcinoma, and non-melanoma skin cancer. 9. Subject has significant uncontrolled medical condition within 6 months prior to enrollment, as determined by the investigator. 10. Subject has concurrent participation in any interventional studies within 14 days of first dose of study drug. 11. Subject has uncontrolled diabetes mellitus, in the judgment of the Principal Investigator. 12. Subject has an active ocular condition that in the opinion of the investigator may alter visual acuity during the course of the study (i.e., ocular inflammatory disease etc.) or a history or anticipation of major ocular surgery (including cataract extraction, intraocular surgery, etc.) during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PU-H71
PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.
Ruxolitinib
Dosing will be in accordance with current package insert and dose subject was on during study entry.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States Cleveland Clinic - Taussig Cancer Institute Cleveland Ohio
United States Karmanos Cancer Institute Detroit Michigan
United States Duke University Medical Center Durham North Carolina
United States MD Anderson Cancer Center Houston Texas
United States Yale Cancer Center New Haven Connecticut
United States Ochsner Clinic Foundation New Orleans Louisiana
United States University of Nebraska Medical Center Omaha Nebraska
United States Abramson Cancer Center - University of Pennsylvania Philadelphia Pennsylvania
United States Mays Cancer Center UT Health San Antonio San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Samus Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events Safety of PU-H71 in combination with ruxolitinib as assessed by the incidence and severity of adverse events (AEs) and serious AEs as determined by the NCI CTCAE v4.03. 12 months
Primary Maximum Tolerated Dose of PU-H71 (MTD) MTD as assessed by the occurrences of dose limiting toxicities of PU-H71 in combination with ruxolitinib. The MTD will be defined as the dose that does not exceed an acceptable threshold of toxicity. 7 months
Primary Recommended Phase 2 Dose of PU-H71 (RP2D) The RP2D is the dose with an acceptable risk/benefit ratio that warrant study in future trials 12 months
Primary Pharmacokinetic profile of PU-H71: Area under the plasma concentration versus time curve (AUC) Area under the plasma concentration versus time curve (AUC) 12 months
Primary Pharmacokinetic profile of PU-H71: Trough plasma concentration (Cmin) Trough plasma concentration (Cmin) 12 months
Primary Pharmacokinetic profile of PU-H71: Peak plasma concentration (Cmax) Peak plasma concentration (Cmax) 12 months
Primary Pharmacokinetic profile of PU-H71: Time to maximum plasma concentration (Tmax) Time to maximum plasma concentration (Tmax) 12 months
Primary Pharmacokinetic profile of PU-H71: Plasma half-life (T1/2) Plasma half-life (T1/2) 12 months
Secondary Treatment Response Treatment response is to be evaluated using the revised IWG-MRT response criteria. 12 months
Secondary Symptom Burden Assessment The symptomatic burden will be serially evaluated using the MPN-SAF TSS. 12 months
Secondary Biological Markers Assess the effects of treatment on biological markers of the disease (i.e., bone marrow histology; JAK2V617F, CALR, or MPLW515L/K allele burden; cytogenetic response; serum cytokine profiles; and other biomarkers of disease activity). 12 months
See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Not yet recruiting NCT06345495 - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Completed NCT02784496 - Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis Phase 2
Completed NCT00069680 - Genetic Analysis of Gray Platelet Syndrome
Active, not recruiting NCT04097821 - Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Phase 1/Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06397313 - RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis Phase 2
Not yet recruiting NCT06024915 - A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets Phase 1
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT02910258 - Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00666549 - Research Tissue Bank
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Completed NCT00606437 - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants Phase 1
Active, not recruiting NCT03952039 - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Phase 3
Not yet recruiting NCT04709458 - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis Phase 1